Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells

被引：174
作者：
Eggermont, Loek J.
Paulis, Leonie E.
Tel, Jurjen
Figdor, Carl G. [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Dept Tumor Immunol, NL-6525 ED Nijmegen, Netherlands
来源：
TRENDS IN BIOTECHNOLOGY | 2014年 / 32卷 / 09期
关键词：
artificial antigen-presenting cell; synthetic dendritic cell; immunotherapy; cancer; LARGE MULTIVALENT IMMUNOGEN; CD8(+) T-CELLS; IMMUNOLOGICAL SYNAPSE FORMATION; CYTOTOXIC LYMPHOCYTES-T; EX-VIVO EXPANSION; PHASE-I TRIAL; DENDRITIC CELLS; ADOPTIVE TRANSFER; MONOCLONAL-ANTIBODIES; METASTATIC MELANOMA;
D O I：
10.1016/j.tibtech.2014.06.007
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Active anti-cancer immune responses depend on efficient presentation of tumor antigens and co-stimulatory signals by antigen-presenting cells (APCs). Therapy with autologous natural APCs is costly and time-consuming and results in variable outcomes in clinical trials. Therefore, development of artificial APCs (aAPCs) has attracted significant interest as an alternative. We discuss the characteristics of various types of acellular aAPCs, and their clinical potential in cancer immunotherapy. The size, shape, and ligand mobility of aAPCs and their presentation of different immunological signals can all have significant effects on cytotoxic T cell activation. Novel optimized aAPCs, combining carefully tuned properties, may lead to efficient immunomodulation and improved clinical responses in cancer immunotherapy.
引用
收藏
页码：456 / 465
页数：10
相关论文
共 88 条
[1]   Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation [J].
Anderson, HA ;
Hiltbold, EM ;
Roche, PA .
NATURE IMMUNOLOGY, 2000, 1 (02) :156-162
[2]  
Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
[3]   Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell [J].
Butler, Marcus O. ;
Lee, Jeng-Shin ;
Ansen, Sascha ;
Neuberg, Donna ;
Hodi, F. Stephen ;
Murray, Andrew P. ;
Drury, Linda ;
Berezovskaya, Alla ;
Mulligan, Richard C. ;
Nadler, Lee M. ;
Hirano, Naoto .
CLINICAL CANCER RESEARCH, 2007, 13 (06) :1857-1867
[4]   Human cell-based artificial antigen-presenting cells for cancer immunotherapy [J].
Butler, Marcus O. ;
Hirano, Naoto .
IMMUNOLOGICAL REVIEWS, 2014, 257 (01) :191-209
[5]   Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles [J].
Cai, Shuang ;
Yang, Qiuhong ;
Bagby, Taryn R. ;
Forrest, M. Laird .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (10-11) :901-908
[6]   IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype [J].
Casey, Kerry A. ;
Mescher, Matthew F. .
JOURNAL OF IMMUNOLOGY, 2007, 178 (12) :7640-7648
[7]   Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers [J].
Champion, Julie A. ;
Katare, Yogesh K. ;
Mitragotri, Samir .
JOURNAL OF CONTROLLED RELEASE, 2007, 121 (1-2) :3-9
[8]   PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine [J].
Cheever, Martin A. ;
Higano, Celestia S. .
CLINICAL CANCER RESEARCH, 2011, 17 (11) :3520-3526
[9]   Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse [J].
Choudhuri, Kaushik ;
Llodra, Jaime ;
Roth, Eric W. ;
Tsai, Jones ;
Gordo, Susana ;
Wucherpfennig, Kai W. ;
Kam, Lance C. ;
Stokes, David L. ;
Dustin, Michael L. .
NATURE, 2014, 507 (7490) :118-+
[10]   T-CELL RECEPTOR-MHC CLASS-I PEPTIDE INTERACTIONS - AFFINITY, KINETICS, AND SPECIFICITY [J].
CORR, M ;
SLANETZ, AE ;
BOYD, LF ;
JELONEK, MT ;
KHILKO, S ;
ALRAMADI, BK ;
KIM, YS ;
MAHER, SE ;
BOTHWELL, ALM ;
MARGULIES, DH .
SCIENCE, 1994, 265 (5174) :946-949
123456789